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Objective To compare quality of life in elderly patients
with isolated systolic hypertension allocated randomly to
groups to receive placebo or active treatment in the
Systolic Hypertension in the Elderly Trial.
Design Double-blind randomized controlled trial.
Methods Patients aged 60 years were allocated randomly
to groups to receive first-line treatment with nitrendipine
(with second- and third-line enalapril and
hydrochlorothiazide) or placebo. Trained interviewers
administered trail-making tests (Trail A and B), Brief
Assessment Index (a measure of depressed mood) and
four subscales from the Sickness Impact Profile
(Ambulation, Social Interaction, Sleep and Rest, and Home
work).
Results Six hundred and ten patients completed a
baseline and at least one follow-up questionnaire. Trail-
making scores were slower in actively treated patients,
especially in the first 6 months of follow-up when the
between-group effect sizes were 0.25 [95% confidence
interval (CI) 0.07 to 0.43] for Trail-making A and 0.13 (95%
CI 0.05 to 0.31) for Trail-making B. Across the 4 years of
follow-up, patients receiving active treatment were more
likely to report problems on the Social Interaction scale
than were placebo-treated patients (odds ratio 1.32, 95%
CI 1.02 to 1.69), equivalent to a 7% difference. There were
no significant differences between active and placebo
treatment in the other Sickness Impact Profile dimensions
or in the measure of depression.
Conclusions Active treatment in the Systolic Hypertension
in Europe trial was associated with some small adverse
impacts on quality of life. J Hypertens 20:2069–2079 &
2002 Lippincott Williams & Wilkins.
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Introduction
There is now substantial evidence from randomized
controlled trials of the benefits of pharmacological
treatment of isolated systolic hypertension in older
people. A recent meta-analysis of eight trials found risk
reductions of 13% for all-cause mortality, 30% for
strokes, and 23% for coronary events [1]. An important
consideration in the treatment of patients with hyper-
tension is that the drugs used to reduce the blood
pressure should not be detrimental to the patient’s
everyday health-related quality of life. In long-term
placebo-controlled treatment trials in older people, the
effects on quality of life have been reported only for
the Systolic Hypertension in the Elderly Program
(SHEP) trial [2,3] and from the Medical Research
Note: This work was presented by A. Fletcher et al. as an oral presentation at the
XIth European Meeting on Hypertension Milan, Italy, 15–18 June, 2001.
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Council (MRC) trial of systolic hypertension for the
substudies measuring cognitive function [4]; the results
for mood disorders are awaited. The Systolic Hyper-
tension in Europe (Syst-Eur) trial, a placebo-controlled
trial of the treatment of elderly patients with isolated
systolic hypertension in Europe also included a side
project to measure health-related quality of life. In this
paper, we report the results of the quality of life
assessment. We have previously presented the baseline
measures of quality of life for 631 patients recruited by
1 October 1995 [5]. The trial was stopped in February
1997 at the second interim analysis when the monitor-
ing boundary for stroke events was crossed in favour of
active treatment.
Methods
The Syst-Eur Trial
The procedure for the Syst-Eur trial has been pub-
lished in full elsewhere [6]. Eligible patients had to be
at least 60 years old and with an average sitting blood
pressure (mean of six measurements obtained at three
visits 1 month apart in the run-in period) of 160–
219 mmHg systolic and .95 mmHg diastolic, and an
average standing systolic pressure of 140 mmHg or
more. After stratification by centre, sex and previous
cardiovascular complications, eligible patients were
randomly assigned to double-blind active or placebo
treatment by means of a computerized random function
at the coordinating office. Active treatment consisted of
nitrendipine (10–40 mg daily) combined, if necessary,
with enalapril (5–20 mg daily) and hydrochlorothiazide
(12.5–25 mg daily). The patients in the control group
received matching placebos. The active drugs were
step-wise titrated to reach goal pressure, which was
defined as a sitting systolic blood pressure less than
150 mmHg, with a reduction from baseline (at the time
of allocation to groups) of at least 20 mmHg. Over an 8-
year period, 4695 patients were recruited into the
study. At the time the trial was stopped, the median
follow-up was 2 years (range 1–97 months). The trial
results showed that active treatment was associated
with a 42% reduction in strokes (P , 0.003) and 26%
reduction in cardiac events (P , 0.03) [7].
Assessment of quality of life
Thirty-three centres in 12 countries participated in the
quality of life side project (see Appendix for full details
of centres and locations). Patients were recruited from
hypertension clinics or general practitioners from cen-
tres in Finland (51%), Italy (12.5%), UK and Ireland
(10%), Russia (5.5%) and Spain (4%), with smaller
numbers from Poland, Belgium, Slovakia, Lithuania,
Romania and Croatia. Full details of the procedure for
quality of life assessment have been published else-
where [8]. The questionnaire, which was administered
by an interviewer, covered a variety of aspects of
quality of life and included well-established and tested
scales.
Section 1 of the questionnaire was two short tests,
Trail-Making Test A and Trail-Making Test B [9]. These
are tests of coordination, visual scanning and visual-
motor speed. In the Trail-making test A, patients were
required to connect up the numbers 1 to 25 sequen-
tially. Trail-making test B consists of an alternating
sequence of numbers and letters that patients must
connect up in the correct sequence. The time taken to
record the sequence correctly for each test was re-
corded. Studies have shown that these tests are able to
pick up deteriorations in performance related to hyper-
tensive arterial changes [10,11].
Section 2 consisted of the following dimensions of the
Sickness Impact Profile (SIP) [12]:
Ambulation: describes the effect of poor health on the
ability to walk and move around freely.
Social Interaction: describes the effects of poor health on
relationships with family and friends, and enjoyment of
social activities.
Home work: describes the effects of poor health on
housework, and other primarily physical activities
related to looking after the home.
Sleep and Rest: describes the effect of poor health on
daytime and night-time rest.
Each section included a set of statements, which were
individually read to the patient. They responded if
they agreed with the statement, and also indicated if it
was due to their health.
Section 3 was the Card Version of the Brief Assessment
Index (BAI) to assess depression [13]. The patient was
asked to respond to each of 19 statements on separate
cards shown to them by the interviewer.
Section 4 consisted of a checklist of 32 symptoms
covering the expected symptoms associated with hyper-
tension and the side effects of the antihypertensive
drugs to be used in the trial. The results of the
symptom assessment are not included in this paper.
The quality of life questionnaires were translated from
English into the local language of each centre. Standard
procedures were followed, including forward and back
translation and further modifications as necessary. All
patients in each centre who entered into the run-in
phase were invited to take part in the side project. The
nature of the questionnaire was explained fully to
patients and full confidentiality was assured. Inter-
viewers attended a training session at the coordinating
centre in the administration of the questionnaire and
tests. In addition, the interviewers were required to
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administer the questionnaire under standard conditions
(separate and quiet room, before the patient saw the
doctor or had their blood pressure measured).
Objectives and sample size calculations
The main objectives of the side project were to com-
pare active and placebo treatments on all five outcomes
(i.e. the four SIP dimensions and the BAI), and the two
tests of Trail-making. On the basis of results from a
pilot study of 52 men and women older than 60 years at
the Hammersmith Hospital, an Æ of 0.01 and power of
90%, we estimated that about 330 individuals in each
group were required to detect an approximately 10%
difference in quality of life measures equivalent to a
0.2 effect size. This number was increased to 400 per
group on the assumption of an 80% response rate to the
side project.
Statistical methods
The SIP dimensions were scored as follows: each
statement had a weighted score and the total dimension
score was the sum of the weighted responses divided
by the maximum available for that dimension, thus
converting the scale to a 0–100 score, with 0 represent-
ing good quality of life (i.e. no problems) and 100
representing poor quality of life (maximum number of
affirmative statements). The weights used in the Syst-
Eur trial were derived from those used in a large study
of disability in the UK [14]. The BAI was scored by
summing all the positive responses; two statements (‘I
have given up hope’ and ‘I have seriously considered
suicide’) were given double scores. The range of scores
in the BAI was 0 (i.e. no problems) to 21 (maximum
problems). Patients’ scores were also expressed as a
percentage of maximum.
We undertook the following analyses:
(1) Analyses based on change from baseline to 6 months and
from baseline to 2 years. The period of 2 years was
chosen because it was the median follow-up time
for all Syst-Eur patients in the main trial. Changes
in SIP and BAI scores were tested using the
Wilcoxon two-sample test for medians. Trail-mak-
ing times were log transformed and analysed by t-
tests. Changes from baseline were calculated by
taking the antilog of the difference between the
log-transformed baseline and follow-up Trail-mak-
ing times and expressing the obtained ratio on a
percentage scale. Between randomized groups,
effect sizes were calculated as the mean differences
of the treatment effects in the active and placebo
groups divided by the pooled standard deviation
and confidence ranges calculated as described by
Hedges and Olkin [15].
(2) Analyses for all patients across the 4-year period of
follow-up time for all patients with a baseline measure-
ment and utilizing all available data for each patient.
The follow-up period did not go beyond 4 years
because very few patients [55 (19%) receiving
placebo and 56 (17%) receiving active treatment]
had completed questionnaires beyond this period.
We used a multilevel modelling approach with
generalized estimating equations [16] to estimate
treatment and time effects taking account of age
and baseline score, and also to check for possible
interactions between treatment and time. For these
analyses, the SIP and BAI scores were dichoto-
mized as no problems (score ¼ 0) or problems
(score .0).
These analyses were conducted for the patient popu-
lation defined by (a) intention-to treat (ITT) and (b) on
randomized treatment (ORT) strategy. All analyses
were performed using SAS 8.0 (SAS Institute, Cary,
North Carolina, USA). The ITT population included
all patients according to their randomization group,
irrespective of whether they had been withdrawn from
the double-blind part of the trial. The ORT analyses
were based only on patients who continued with
double-blind treatment.
Results
Figure 1 shows the flow chart for the study. The 33
centres participating in the quality of life side project
included about 25% of all trial patients. However,
because of the time taken to start the quality of life
side project in the centres (ethics approval, translation
of questionnaires and nurse training), about 33% of the
potential patients had already been allocated to groups
and therefore were not included. In each arm of the
study, just over 100 patients who should have partici-
pated in the quality of life side project did not do so,
but the reasons for not being included were largely
unknown. Of the 344 patients in the placebo group and
the 364 active-treatment patients who completed a
baseline questionnaire, 289 and 321, respectively, also
completed at least one follow-up questionnaire; 55 in
the placebo group and 43 in the active-treatment group
did not complete any follow-up questionnaires, the
reason for non-completion being unknown in the
majority of cases (most of these patients were still
receiving double-blind treatment). The numbers in the
ITT and ORT analyses were similar: for placebo, 289
in ITT and 276 in ORT, and for the actively treated
group, 321 in ITT and 317 in ORT. In the ITT
analysis, questionnaires were available for 47% of pa-
tients who received placebo and were followed for at
least 4 years, and for similar proportions (46%) in the
active-treatment group. For the ORT analysis, 34% of
those receiving placebo and 39% of those in the active-
treatment group provided questionnaires for at least
4 years. In the early part of the trial, questionnaires
were available at the second year of follow-up for 82%
Quality of life in the Syst-Eur Trial Fletcher et al. 2071
of both groups for the ITT analyses, and for 67% of
placebo-group patients and 75% of active-treatment
group patients for the ORT analyses, reflecting the
earlier and greater rate of withdrawal from the placebo
group.
Table 1 gives the characteristics and scores for Trail-
making tests and quality of life by randomized treat-
ment at baseline for the 610 patients who completed at
least one follow-up quality of life questionnaire. Pa-
tients in the active-treatment and placebo groups were
Randomized in Syst-Eur main
trial
n  4695
Randomized in 33 centres
participating in quality of life
side project
n  1348
Randomized before start of QOL project  217
No QOL  119
Reasons
Missed/refused  15
Reason unknown  104
Completed baseline QOL  344
Placebo
n  680
Active
n  668
Randomized before start of QOL project  195
No QOL  109
Reasons
Missed/refused  4
Reason unknown  105
Completed baseline QOL  364
Baseline and at least one follow-up
questionnaire  289
Did not complete any follow-up
questionnaires  55
Reasons
Died  6
Stopping of main trial  5
Refused  8
Non-supervised open follow-up  5
Not known  31
Baseline and at least one follow-up
questionnaire  321
Did not complete any follow-up
questionnaires  43
Reasons
Died  1
Stopping of main trial  2
Refused  3
Non supervised open follow-up  7
Not known  30
Fig. 1
Study flow chart.
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similar for most demographic and clinical variables. In
both groups, SIP scores were low, with median values
of 0 for three of the four SIP dimensions, and a median
of 3.5 on the social interaction dimension. The median
BAI score was also low (4.8) compared with a recom-
mended cut-off point of 15 for possible clinical depres-
sion. Thus, at entry to the trial, patients reported little
disability and showed high levels of social interaction
and mental well-being. The patients in the quality of
life side project were also very similar to those in the
main trial [7] in respect of all entry characteristics, with
the exception of previous antihypertensive medication
(in the quality of life project, 34% in the placebo group
and 33% in the active treatment group had previously
been treated, compared with 47 and 46%, respectively,
in the main trial). Those eligible for the quality of life
project but who did not participate were also less
healthy than participants (46% of non-participants had
cardiovascular complications at entry, compared with
32% of participants, and 51% had been treated pre-
viously).
Treatment effects
Quality of life (SIP and BAI)
Table 2 presents the results for the ITT population for
changes from baseline in SIP and BAI scores at the two
time-points of 6 months and 2 years. No differences
between active and placebo treatments were observed.
The ORT analyses for these time-points were essen-
tially similar. Figure 2 shows the proportions scoring
.0 on each of the SIP and BAI scores over the 4 years
Table 1 Characteristics of patients at baseline
Placebo
(n ¼ 289)
Active treatment
(n ¼ 321)
Age (years) 70.2  6.0 70.8  6.3
Men 91 (31.5) 96 (29.9)
Systolic blood pressure (mmHg) 172.2  9.9 173.3  10.6
Diastolic blood pressure (mmHg) 86.6  5.4 85.6  5.7
BMI (kg/m2)
Men 26.2  2.9 26.4  3.5
Women 27.6  4.4 26.9  3.9
Cardiovascular complications 94 (32.5) 102 (31.8)
History of stroke 4 (1.4) 7 (2.2)
History of myocardial infarction 7 (2.4) 9 (2.8)
Diabetes 20 (6.9) 23 (7.2)
Current smokers 24 (8.3) 28 (8.7)
Current drinkers 98 (34.0) 109 (34.0)
>1 unit alcohol/day 34 (11.8) 42 (13.1)
Previous treatment 97 (33.6) 105 (32.7)
ADL score 6 284 (98.3) 320 (99.7)
Trail-making test A (s) 81  64 78  47
Geometric mean 58 (n ¼ 281) 59 (n ¼ 317)
Trail-making test B (s) 190  121 201  145
Geometric mean 154 (n ¼ 273) 153 (n ¼ 303)
Ambulation
Median (interquartile range) 0 (9.2) 0 (9.2)
% .0 43 40
Social interaction
Median (interquartile range) 3.5 (9.8) 3.5 (11.7)
% .0 55 54
Home work
Median (interquartile range) 0 (8.6) 0 (5.4)
% .0 38 41
Sleep and rest
Median (interquartile range) 0 (14.5) 0 (14.5)
% .0 33 27
Brief assessment index
Median (interquartile range) 4.8 (9.5) 4.8 (14.3)
% .0 56 59
Values are mean  SD, number (%), or number. BMI, body mass index; ADL,
activities of daily living.
Table 2 Within-treatment changes in quality of life measures from baseline to 6 months and 2 years
(intention-to-treat analysis)
Differences from baseline at:
6 months{ 2 years{
Placebo
(n ¼ 232)
Active treatment
(n ¼ 263) P{
Placebo
(n ¼ 236)
Active treatment
(n ¼ 264) P
Sickness impact profile
Ambulation
Median 0 0 0 0 0.44
5th to 95th PI 13 to 11 11 to 13 0.50 12 to 15 13 to 15
Social interaction
Median 0 0 0 0 0.38
5th to 95th PI 13 to 14 13 to 7 0.48 17 to 14 19 to 9
Home work
Median 0 0 0 0 0.46
5th to 95th PI 16 to 11 13 to 17 0.10 14 to 16 13 to 24
Sleep and rest
Median 0 0 0 0 0.14
5th to 95th PI 23 to 19 14 to 14 0.69 25 to 14 16 to 14
Brief assessment index
Median 0 0 0 0
5th to 95th PI l 14 to 10 14 to 10 0.97 14 to 14 19 to 14 0.41
{A negative score denotes improvement; {P value for difference in medians. PI, percentile interval.
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Fig. 2
Proportions of patients scoring more than 0 in the randomised treatment analyses for Sickness Impact Profile for (a) ambulation, (b) social
interaction, (c) sleep and rest and (d) home work, and for (e) the Brief Assessment Index.
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of follow-up. In the multilevel model for the ITT
population, and taking account of baseline scores, sig-
nificant time trends were observed for ambulation and
home work, with the proportion reporting problems
increasing over the years of follow-up, but there were
no differences between active and placebo treatments
in the rate of increased reporting of problems (Table
3). The social interaction scale showed no time effects,
but significant treatment differences in favour of place-
bo (P ¼ 0.03). The odds ratio for an adverse effect of
active treatment on social interaction was 1.32 [95%
confidence interval (CI) 1.02 to 1.69]. The ORT
analyses showed similar results and, in addition, a
significant time-by-treatment interaction for home
work, with greater improvements for patients receiving
placebo at the last period of follow-up.
Trail-making performance (Trail-making tests A and B)
When changes in time to complete Trail-making tests
A and B were compared at the 6-month time-point,
patients taking placebo had greater improvements than
did those receiving active treatment (Table 4). A
significant difference (P ¼ 0.006) was observed for
Trail-making A, whereas for Trail-making B the differ-
ences were not significant (P ¼ 0.15). There were no
differences at the 2-year time-points for either Trail-
making A or Trail-making B. The ORT analyses were
essentially identical. Figure 3 shows the results over
the 4 years of the trial. In the multilevel analysis for
Trail-making A using the ITT population, taking
account of all data in the 4-year follow-up period,
significant treatment effects in favour of placebo
(P ¼ 0.01) were shown, together with a significant time-
by-treatment interaction (P ¼ 0.03), mainly as a result
of larger differences being observed in the earlier
period of follow-up (Table 5). The results for Trail-
making B for the ITT population showed smaller
treatment effects (P ¼ 0.07) and significant time-by-
treatment interactions (P ¼ 0.03). The ORT analyses
for Trail-making A showed significant treatment effects
in favour of placebo (P ¼ 0.05) across the 4 years of the
trial, but no time-by-treatment interaction (P ¼ 0.10).
For Trail-making B, the ORT analyses showed no
significant treatment effects (P ¼ 0.56), or time-by-
treatment effects (P ¼ 0.14), although completion times
tended to be slower in those receiving active treatment
in the earlier part of the follow-up period.
In the Trail-making analyses, we excluded a small
proportion of patients (around 3% at each time point)
who had either incorrectly completed or been unable to
complete the task. We re-ran all analyses, including
these patients and assigning their scores to the slowest
score recorded for patients who had completed the task
correctly. The results were virtually unchanged from
those reported above.
In order to investigate whether the 6-month differences
were related to the greater decreases in blood pressure
observed in those receiving active treatment, we exam-
ined the correlations between changes in systolic pres-
sure and changes in completion times. The correlation
coefficients were extremely low: r ¼ 0.08 (P ¼ 0.24)
and r ¼ 0 (P ¼ 1.0) for Trail-making A and systolic
blood pressure for the placebo and active-treatment
groups, respectively, and r ¼ 0.06 (P ¼ 0.41) and r ¼
0.04 (P ¼ 0.53) for Trial-making B. Adjusting for blood
pressure over follow-up in the multilevel models also
did not change the results observed for either the
Trail-making tests or the quality of life scores.
Discussion
The results from the quality of life assessment in the
Syst-Eur trial suggested that active treatment had some
Table 4 Changes in Trail-making tests{ from baseline to 6 months and to 2 years (intention-to-treat analysis)
Differences from baseline{ at:
6 months 2 years
Placebo Active treatment P Placebo Active treatment P
Trail-making test A (n ¼ 227) (n ¼ 261) (n ¼ 230) (n ¼ 259)
% change 16.3 8.4 0.006 15.8 13.6 0.46
95% CI 20.3 to 2.0 12.1 to 4.6 20.2 to 11.3 17.3 to 9.7%)
Trail-making test B (n ¼ 219) (n ¼ 249) (n ¼ 223) (n ¼ 251)
% change 10.2 5.9 0.15 10.5 10.9 0.89
95% CI 14.4 to 5.7 9.8 to 1.8 15.0 to 5.8 15.4 to 6.2
{The reported figures are geometric means expressed as a percentage (antilog of a difference between two log-transformed
variables is a ratio). {Negative score denotes improvement in time to complete task. CI, confidence interval.
Table 3 Age-adjusted estimates of treatment and time effects from
multilevel model for the intention-to-treat population
Treatment effect Time effect{
Ambulation 0.99 (0.74 to 1.33) 1.27 (1.18 to 1.37)
Social interaction 1.32 (1.02 to 1.69) 1.04 (0.97 to 1.12)
Home work 1.13 (0.84 to 1.53) 1.10 (1.02 to 1.19)
Sleep and rest 0.84 (0.65 to 1.08) 1.06 (0.98 to 1.14)
Brief Assessment Index 0.95 (0.74 to 1.19) 0.99 (0.93 to 1.07)
Values are odds ratio and 95% confidence intervals. {Per year of follow-up.
Quality of life in the Syst-Eur Trial Fletcher et al. 2075
adverse impacts on quality of life compared with
placebo. Although the analyses of changes from base-
line to two time-points (6 months and 2 years) found no
significant differences for any of the SIP dimensions,
an analysis that included data from all time-points over
the 4 years of follow-up and also adjusted for age and
baseline values showed significant between-group dif-
ferences, with greater proportions of actively treated
patients reporting problems on the social interaction
dimension. These problems may reflect treatment side
effects observed in the trial, of which the most impor-
tant were flushing, oedema and headache with nitrendi-
pine, and cough with enalapril [17]. No overall
treatment differences were observed for the SIP dimen-
sions, which measure aspects of physical functioning
(ambulation and home work), or with problems with
sleep, although there was some suggestion of an
adverse treatment effect in the 4th year of follow-up
for the dimension ‘home work’. The SHEP trial used
different measures of quality of life than Syst-Eur, but
included some questions on similar areas. In that trial,
Activity of Daily Living measures showed a small
deterioration in both groups, but there were no differ-
ences in overall scores between the two groups [3]. For
some individual activities (e.g. dressing, eating, using
the toilet, going upstairs and some leisure activities
such as taking walks), there were small benefits in
favour of the active treatment group. These differences
were not explained by the reduced cardiovascular
events in that group.
Reassuringly, there were no adverse effects from active
treatment on measures of depression in the Syst-Eur
trial. In the SHEP trial there was some evidence for a
worsening of mood scores among those receiving place-
bo which, although statistically significant, was of a very
small magnitude [3].
The results from the Syst-Eur trial showed a slower
rate of learning of the Trail-making tests in actively
treated patients. The largest difference was in the first
6 months of follow-up and was not related to the
magnitude of the blood pressure reduction. It might be
expected that patients receiving placebo, with a smaller
reduction in blood pressure, would show a reduced
learning effect compared with actively treated patients
who had larger decreases in blood pressure, especially
in the first 6 months of treatment (20 mmHg in the
active treatment group and 10 mmHg in the placebo
group). Previous studies have suggested an inverse
association between blood pressure and cognitive per-
formance, especially for memory and attention [18].
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Times to complete Trail-making tests A and B. (Incorrect and
unfinished tests were excluded)
Table 5 Regression coefficients for the Trail-making tests from the multilevel model for the intention-to-
treat population
Treatment effect{ Time effect Interaction
Trail-making A 0.0305 (0.0072 to 0.0538) 0.0036 (0.0023 to 0.0095) 0.0092 (0.0174 to 0.0010)
Trail-making B 0.0216 (0.0021 to 0.0453) 0.0065 (0.0006 to 0.0136) 0.0111 (0.0211 to 0.0011)
{The treatment effects at z years are the ratio of active/placebo given by the equations:
10(0:0305z[0:0092]) for Trail-making A, and 10(0:0216z[0:0111]) for Trail-making B.
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However, the evidence is strongest for associations
between blood pressures measured in mid life and
subsequent cognitive decline [19,20].
One of the difficulties in disentangling the relationships
between blood pressure and cognitive functioning is
that antihypertensive drugs might interfere with certain
aspects of cognitive functioning and hence negate any
benefits of blood pressure decreasing. An adverse effect
on performance in Trail-making tests has clearly been
demonstrated for older classes of drugs, such as methyl-
dopa [21], with effect sizes of 0.3 for the difference
with captopril at 6 months, where effect sizes of 0.3 are
considered to represent a small but noticeable treat-
ment effect, and those of 0.2 or less are considered to
be of minimal impact. In comparison, in the present
study, the between-group effect sizes at 6 months were
0.25 (95% CI 0.07 to 0.43) for Trail-making A and 0.13
(95% CI 0.05 to 0.31) for Trail-making B. The
evidence for other drugs is mixed. In middle-aged
hypertensive patients, negligible between-drug differ-
ences in Trail-making tests, or other measures of
memory or alertness, have been found in trials that
have compared a range of classes of antihypertensive
agents, including calcium channel blockers (such as
nifedipine) and angiotensin-converting enzyme inhibi-
tors (including enalapril) [22]. In older hypertensive
patients, the evidence is less reassuring. A small cross-
over trial of atenolol and nifedipine, using an intensive
battery of tests, found significant differences in favour
of atenolol in short- and long-term measures of recall
[23]. Previous placebo-controlled long-term trials in
older people have not found differences between active
treatment and placebo in performance on cognitive
tests.
In the MRC trial of older people, in a substudy of more
than 2000 patients, no differences between placebo or
first-line treatment with diuretic or atenolol in measures
of memory and attention (including Trail-making A)
were observed either in the short term (9 months) or
over 4.5 years of follow-up [4]. These findings were
consistent in both the per-protocol and intention-to-
treat analyses. The differences between placebo, ateno-
lol and hydrochlorothiazide in the rate of learning of
the psychomotor tests were effect sizes of less than
0.05 – that is, one-twentieth of a standard deviation
difference. The SHEP trial included a measure of
cognitive function in all patients; in addition, in six
centres in the trial (with 2000 patients), more detailed
and specific tests of cognitive functioning were meas-
ured. No differences were observed in the general
measure of cognitive function or the more detailed
tests. However, patients receiving active treatment
reported significantly more troublesome or intolerable
problems with memory and concentration compared
with placebo (26 compared with 20%, P , 0.0001) [2].
We did not include either tests of memory or self-
reports of memory problems.
The small slowing down of actively treated patients
was more noticeable for the simpler task of Trail-
making A. Order effect may be a possible explanation
for this, because Trail-making A was consistently given
before Trail-making B, so that larger treatment differ-
ences might be more likely to show up on the first test,
whereas Trial-making B performance would reflect
some practice effects from Trail-making A [24]. Trail-
making B is a more complex task, but may be subject
to more ‘background noise’, because it is affected by
other factors such as reading skills [25]. The reduction
in the size of the placebo–active treatment differences
over follow-up, especially after 2 years of follow-up,
was more attributable to an attenuation of the faster
performance in Trail-making in the placebo group,
perhaps as a result of adverse vascular events.
In the Syst-Eur trial, it is difficult to attribute the
observed effects to one particular drug, because pa-
tients were allocated randomly to a drug regimen and
not to individual drugs. The social interaction results
were relatively constant across the trial, although the
proportions of individuals taking first-line drugs varied.
However, it is likely that the Trail-making results,
which were most pronounced at 6 months, may be
related to nitrendipine treatment, because, at the 6-
month period, 57% of individuals were taking this as
the first-line drug alone, and a further 13% were taking
nitrendipine in combination with one or both of the
second- and third-line drugs; 10% were taking enalapril
only, and two patients were taking hydrochlorothiazide
only.
Our results on social interaction and Trail-making per-
formance also need to be considered in the light of the
positive benefit from active treatment in stroke (42%
reduction), all cardiovascular endpoints (31% reduction)
[7] and a lower incidence of dementia (7.7 per 1000
person years with placebo compared to 3.8 per 1000
person years with active treatment, P ¼ 0.05) [26]. The
size of adverse effects reported in this paper were
small. There was an increased odds ratio of 1.32 for
reporting problems on the social interaction scale, but
the confidence intervals were wide (1.02 to 1.69) and
the proportion who reported no problems was high
even after 4 years of follow-up (46% receiving active
treatment and 53% receiving placebo). For the Trail-
making tests, the overall effect of active treatment was
a 7% increase in time to complete Trail-making A and
a 5% increase for Trail-making B. This attenuated with
follow-up, such that, by the 1-year point, the treatment
effect was 5% for Trail-making A and 2% for Trail-
making B. However, it is possible that adverse effects
may have been underestimated, as participants in the
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quality of life study were more likely to be newly
treated for hypertension and also had fewer cardio-
vascular complications than non-participants. Whether
better effects on quality of life in older individuals with
hypertension would be observed with other classes of
antihypertensive drugs is being investigated in current
trials [27,28].
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